According to Aiqi's investigation, Shandong Lixin Pharmaceutical Company's products have passed the production and quality management system certification of FDA, EMEA, EDQM and GMP, and have five categories 13 raw materials and preparation products, such as anti-tumor, cardiovascular and cerebrovascular diseases, hepatitis B treatment, digestive system treatment and anti-Alzheimer's drugs, and some products are in the leading position in the world. At the same time, the company has three advantages: first, it has strong R&D strength and a professional R&D team of more than 40 people led by three returnees; Second, the level of partners is high, and we have established long-term cooperative relations with well-known domestic and foreign pharmaceutical companies such as Sanofi, China Resources Shuanghe and Qilu Pharmaceutical. Third, the product has outstanding advantages.
Shandong Lixin Pharmaceutical Co., Ltd. is jointly invested and built by Suzhou Terui Pharmaceutical Co., Ltd. and Suzhou Lixin Pharmaceutical Co., Ltd. The project covers an area of 130 mu with a total investment of 370 million yuan. It mainly produces a series of high-end characteristic raw materials and preparations such as anti-tumor, psychoneurosis, cardiovascular and cerebrovascular diseases. The company started construction in August 2065, 438+07.